Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 0.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2 | 0.67 |
NAV | ₹63.99 | ₹17.51 |
Fund Started | 18 Jun 2012 | 11 Jan 2021 |
Fund Size | ₹3221.37 Cr | ₹3183.90 Cr |
Exit Load | Exit load of 1% if redeemed within 1 month. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 23.68% | 30.53% |
3 Year | 11.32% | 12.02% |
5 Year | 15.31% | - |
1 Year
3 Year
5 Year
Equity | 98.27% | 0.00% |
Cash | 1.73% | 100.00% |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
MarketAxess Holdings Inc | 2.86% |
Altria Group Inc | 2.76% |
Bio-Rad Laboratories Inc A | 2.65% |
Gilead Sciences Inc. (USA) | 2.64% |
Corteva Inc. | 2.62% |
Bristol-Myers Squibb Co | 2.54% |
Kenvue Inc. | 2.53% |
International Flavors & Fragrances Inc | 2.50% |
Pfizer INC | 2.50% |
U.S. Bancorp | 2.45% |
Name | Ritesh Lunawat | Arjun Khanna |
Start Date | 28 Dec 2020 | 25 Oct 2023 |
Name
Start Date
Description | The investment objective of ICICI Prudential US Bluechip Equity Fund is to provide long term capital appreciation to investors by primarily investing in equity and equity related securities of companies listed on recognized stock exchanges in the United States of America. The Scheme shall also invest in ADRs/GDRs issued by Indian and foreign companies. | The scheme seeks to provide long-term capital appreciation by investing in units of overseas ETF's and/ or Index Fund based on NASDAQ 100 Index. |
Launch Date | 18 Jun 2012 | 11 Jan 2021 |
Description
Launch Date